← back to rankingMCK · McKesson Corporation
Medical - Distribution · mkt cap $88.6B · calls: Q4 FY2026 vs Q3 FY2026
37.0 conviction · conf-adj 37
conf 3/10 partial
enthusiasm:24.0 · trend:0 · quantifies:0 · impact:0 · under_radar:0 · credibility:0 · business_impact:4 · disruption:0 · commitment:6 · confirmation:3
Enthusiasm latest 8 / prev 8 (flat)
McKesson’s AI thesis is operational and workflow-led: automate provider documentation, patient access workflows, customer inquiries, contact centers, and supply-chain planning. Credibility is relatively high because management gave concrete deployment and productivity metrics, including 1,900 Ambient Scribe users, 120 more patients per FTE, 75% DSCSA inquiry deflection, and near-100% pilot accuracy. The latest call broadened the AI story across oncology, biopharma services, and distribution, but enthusiasm is flat versus Q3 because the prior call had more detailed Q&A and sharper proof points.
GROUNDED NEXT-FY IMPACT vs CONSENSUS
Grounded on actual base — revenue $403.4B · net income $4.8B · net margin 1.2% · diluted EPS 38.38
These are next-fiscal-year annual uplift estimates, not next-quarter numbers.
Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: unclear · priced in: high (model's call-read: medium; verdict above is the hard-data one used for ranking) · confidence: 3/10
| Claim | Figure | Arithmetic | Next-FY Rev % | Next-FY EPS % |
|---|
Ambient Scribe: >1,900 oncology providers
engagement · soft | >1,900 providers | Adoption count only. No revenue-per-provider, cost-saving per scribe, or fee disclosed in any claim; cannot map to $ against $403.43B revenue or $4.762B NI. rev/eps=null. | | |
Verification productivity: +120 patients/FTE
productivity · soft | 120 more patients per FTE/yr | Productivity ratio with no anchor: FTE headcount, $/patient, and fully-loaded FTE cost all undisclosed in any claim. after_tax_saving=(saving)*(1-0.21) uncomputable because saving_$ has no base. null. | | |
Verification productivity (Q3 restatement): +120 patients/FTE
productivity · soft | 120 more patients per FTE/yr | Same 120 incremental patients/FTE figure as Q4, referencing the same annual verification season; not separately additive, and same missing base (no FTE count, no $/patient). null. | | |
Contact-center pilot: ~100% accuracy/reliability
productivity · soft | close to 100% accuracy, reduced turnaround | Quality/pilot metric, not a cost or revenue figure. No baseline error rate, call volume, labor cost, or revenue conversion base; still in pilot. Cannot size. null. | | |
DSCSA deflection: 75% of inquiries not escalated
cost · soft | 75% inquiry deflection | Deflection rate with no base: inquiry volume and cost-per-escalation undisclosed in any claim. saving_$=0.75*inquiries*$/escalation, both unknown, so after-tax saving / $4.762B NI is null. | | |
Prescription Tech Solutions op-margin +130bps YoY
cost · soft | >130 bps op-margin expansion | Anchored % but no obtainable base: PTS segment revenue/profit not given in any quantified claim, so 130bps cannot be converted to $ (would need segment_rev*1.30%*(1-0.21)/$4.762B NI). Also only partly AI-attributable (framed as broad automation). % with no base -> soft. null. | | |
Assumptions: Default tax rate 21%; incremental net margin would default to current 1.18% (net income $4.762B / revenue $403.43B) for any sized revenue claim, but NONE of the six claims carries a dollar base (per-provider fee, FTE count, $/patient, inquiry volume, or PTS segment revenue) anywhere in the inputs, so every claim resolves to soft/null per the rule that a '%' or productivity ratio with no obtainable base is unanchored. No phasing assumed because nothing quantified to phase. All six are internal AI-adoption/efficiency metrics improving MCK's own distribution/pharma-services operations — none sell AI capacity — so 100% adopter-side, 0 supplier-side.
Top line: No hard revenue uplift is computable. Every AI initiative disclosed is an internal efficiency/productivity or quality metric (scribe adoption, verification throughput, contact-center accuracy, DSCSA deflection, PTS margin) — none a revenue or bookings figure. On a $403.4B distribution base any of these would be a rounding error even if sizable. est_rev_uplift_pct=null (not 0 — directionally positive via capacity, but unmeasurable).
Bottom line: Directionally accretive but unsizable. The 130bps PTS margin gain, +120 patients/FTE, and 75% deflection clearly help the bottom line, but with segment-revenue, FTE-count, and inquiry-volume bases all undisclosed, no after-tax saving can be computed against the $4.762B NI base. On thin ~1.18% net margins efficiency matters more than topline, but management frames these as 'targeted investments' whose 'impact will continue to build over time' — not yet a step-change to FY27 EPS.
[impact n/m (all claims soft/unanchored)] Consensus FY2027 revenue $432.873B vs $403.430B current (+7.30%) and net income $5.492B vs $4.762B (+15.33%) — EPS growth far outpacing revenue implies ~9bps of enterprise net-margin lift already baked in (1.180%->~1.27% by FY27). The AI efficiency program is exactly that operating-leverage story, so the qualitative claims look largely consistent with (absorbed by) consensus. Because none of the six claims is quantified to a dollar, there is no measurable gap above or below the trajectory — hence 'unclear' vs expectations and 'medium' priced-in.
MODEL CONSENSUS (impact)
partial
All six claims agree as soft/null adopter-side; only supplier base, priced_in, and confidence differed.
Conflicts reconciled
- supplier_rev_uplift_pct: X=0 vs Y=null -> used 0 because zero supplier-side claims means a defensible exact 0
- priced_in: X=high vs Y=medium -> used medium because Y's specific consensus-margin-trajectory math (~9bps lift baked in) is better justified than X's general assertion
- confidence: X=4 vs Y=3 -> used 3 (avg 3.5 rounded down, conservative on category disagreement)
| Field | Opus 4.8 | GPT-5.5 |
|---|
| Rev uplift % | – | – |
| EPS uplift % | – | – |
| Priced in | medium | high |
| vs analysts | unclear | unclear |
| Confidence | 3 | 4 |
| Top line | Effectively zero quantifiable topline impact. Every AI initiative disclosed is an internal efficiency/productivity or quality metric (scribe adoption, verification throughput, contact-center accuracy, DSCSA deflection, PTS margin). None is a revenue or bookings figure, and on a $403.4B distribution base any of these would be a rounding error even if sized. est_rev_uplift_pct = null (not 0 — directionally positive via capacity, but unmeasurable from disclosed figures). | No hard revenue uplift is computable. The disclosed AI figures are adoption, productivity, deflection, accuracy, and segment-margin metrics without dollar or volume bases. |
| Bottom line | Directionally accretive but unsizable. The 130bps PTS margin gain and the +120-patients/FTE and 75%-deflection efficiencies clearly help the bottom line, but with the segment-revenue, FTE-count, and inquiry-volume bases all undisclosed, no after-tax saving can be computed against the $4.762B net-income base. On thin 1.18% net margins, efficiency gains matter more than topline — but management itself frames these as 'targeted investments' whose 'impact will continue to build over time,' i.e. not yet a step-change to FY27 EPS. | Likely directionally positive, but not quantifiable from the provided facts. Even the strongest operating claim, 130 bps Prescription Technology Solutions margin expansion, lacks the required segment revenue base. |
| Reasoning | Consensus already embeds margin expansion: implied net margin rises 1.180% (current) -> 1.186% (FY26) -> 1.269% (FY27), with FY27 EPS growth of 13.4% on only 6.0% revenue growth — i.e. ~9bps of enterprise margin lift is already baked in. The AI efficiency program is exactly the kind of operating-leverage story that gap represents, so the qualitative claims look consistent with (largely absorbed by) consensus rather than incremental to it. Because none of the six claims is quantified to a dollar, there is no measurable gap above or below the trajectory — hence 'unclear' vs expectations and 'medium' priced-in rather than the interesting 'low.' | Consensus FY2027 revenue is $432.873B vs $403.430B current, implying +$29.443B or +7.30%; consensus FY2027 net income is $5.492B vs $4.762B, implying +$729.8M or +15.33%. The disclosed AI claims do not provide a hard incremental $ impact to compare against that trajectory. |
Rows highlighted where the two models disagreed.
QUANTIFICATIONS
Ambient Scribe adoption: more than 1,900 providers (Q4 FY2026, bottomline)
“Within the U.S. Oncology Network, Ambient Scribe technology is now used by more than 1,900 providers.”
Annual verification productivity: 120 more patients per full-time employee (Q4 FY2026 season compared to last year, bottomline)
“As a result, each full-time employee supported 120 more patients this season compared to last year.”
Annual verification productivity: 120 more patients per full-time employee (Q3 FY2026 annual verification season compared to last year, bottomline)
“As an example of this, in our annual verification season, each full-time employee is successfully supporting 120 more patients than we achieved last year.”
Contact center pilot accuracy and reliability: close to 100% (Q3 FY2026 early pilots, bottomline)
“Our early pilots are demonstrating strong results, close to 100% service accuracy and reliability while reducing turnaround time.”
DSCSA inquiry deflection: 75% of inquiries (Q3 FY2026 after November launch, bottomline)
“By enabling natural language answers to complex DSCSA data questions, we prevented 75% of inquiries from being escalated and materially improved first contact resolution.”
Prescription Technology Solutions operating margin expansion linked to automation strategy: over a 130 basis points year over year (Q3 FY2026 year over year, bottomline)
“If you look at the segment, we've seen operating margins grow over a 130 basis points year over year. So, again, focusing on positioning our capabilities and our services to automate those products for for biopharma partners is gonna continue to improve that trajectory going forward.”
PAST (realized)
- Q4 FY2026 | Brian Tyler: "As a result, each full-time employee supported 120 more patients this season compared to last year."
- Q4 FY2026 | Britt Vitalone: "This transformation enables us to deliver working capital savings and meaningfully contributed to the strong operating cash flow in fiscal 2026."
- Q3 FY2026 | Brian Tyler: "In the US, we launched an AI chat tool in November to specifically handle customer inquiries related to the Drug Supply Chain Security Act."
- Q3 FY2026 | Brian Tyler: "By enabling natural language answers to complex DSCSA data questions, we prevented 75% of inquiries from being escalated and materially improved first contact resolution."
CURRENT (now)
- Q4 FY2026 | Brian Tyler: "As we scale the platform, we're embedding automation and AI to improve workflow and enhance the patient experience."
- Q4 FY2026 | Brian Tyler: "Within the U.S. Oncology Network, Ambient Scribe technology is now used by more than 1,900 providers."
- Q4 FY2026 | Brian Tyler: "Across our supply chains, AI-driven inventory planning capabilities are helping us move from reactive to more technology-enabled real-time decision-making."
- Q3 FY2026 | Brian Tyler: "Within our North American pharmaceutical business, our teams continue to leverage AI and automation to drive efficiencies."
FORWARD (guidance)
- Q4 FY2026 | Britt Vitalone: "We achieved this operating efficiency while simultaneously making targeted investments to modernize our operations through automation and AI-driven capabilities, which we anticipate will accelerate growth, creating enterprise-wide efficiencies."
- Q3 FY2026 | Britt Vitalone: "At the same time, we're making targeted investments to modernize our operations through automation and AI-driven capabilities, which we anticipate will accelerate growth while creating enterprise-wide efficiencies."
- Q3 FY2026 | Operator: "we would expect that impact will continue to build over time."
TRACK RECORD — PROMISE vs DELIVERY
—/100 (no quantified promises) no-quantified-promises 6 calls reviewed
Across these six McKesson calls, management repeatedly cites AI/automation results that were already achieved — distribution centers up to 90% automated, CoverMyMeds virtual assistant automating 20%+ of chats, a DSCSA chatbot deflecting 75% of inquiries, Ambient Scribe on ~1,900 providers, and +120 patients supported per FTE — but none of these is a forward-looking quantified target pairing a number with a future date or milestone. With no prior quantified AI promise to judge, there is no promise-vs-delivery track record to score.
PRICED-IN (REFINED)
HIGH (already in)Est. revisions rising · Fwd P/E 18.9 · EV/Sales 0.2x
AI claim maps to Prescription Technology Solutions Segment, North American Pharmaceutical Segment, Oncology And Multispecialty Segment
Analyst ratings have migrated upward from January to June with more strongBuy/buy ratings and fewer hold/negative ratings, while forward EPS estimates imply double-digit annual growth. Price targets are not perfectly monotonic, but recent averages remain well above the last-year average, supporting a rising revision backdrop. At a 18.9x forward P/E for a mature medical distributor, with AI most plausibly flowing through Prescription Technology Solutions and operating leverage in pharmaceutical distribution, rising estimates make the AI upside more priced-in rather than less.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
2Q3 FY20257Q4 FY20255Q1 FY20266Q2 FY20268Q3 FY20269Q4 FY2026
AI enthusiasm across 6 calls — trend ↗ rising
AI moved from absent to concrete automation, agent assist, inquiry deflection, ambient scribe adoption, and integrated access workflows.
RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY
6/10 qualitative impact moderate medium-term · mixed evidence
Where AI matters: provider workflows, patient access, contact centers, supply-chain planning
McKesson has concrete AI deployments in oncology scribing, patient verification, DSCSA inquiry deflection, contact-center pilots, and inventory planning, so this is more than narrative. But the disclosed metrics mostly improve productivity and workflow quality, with no dollarized revenue or EPS bridge and limited evidence that AI changes the economics of the $400B-plus distribution core.
Caveats: Efficiency gains may be too small to matter at enterprise scale without dollarized savings.; Benefits are concentrated in workflows and services, not the dominant distribution revenue base.; AI claims include pilots and productivity ratios with missing volume, cost, and margin anchors.; Execution, compliance, data quality, and clinical documentation liability could limit rollout.
AI DISRUPTION / CANNIBALIZATION RISK tailwind · 2/10
AI does not directly commoditize regulated drug distribution, purchasing scale, logistics infrastructure, or provider/manufacturer relationships. Some admin workflow services could be automated, but McKesson appears positioned to capture that automation through its own platforms rather than lose the core revenue model.
OPTIONS / MARKET STRUCTURE
option liquidity: good
proxy inputs — dollar-ADV $745M · beta 0.355 · px $736.78
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.
CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 8/10 committed.
INSIDERS selling 7 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 193 new / 164 closed positions; 906 increased / 793 reduced; institutional ownership -2.27pp; +32 net 13F holders
MGMT LANGUAGE 8/10 committed Multiple concrete deployments, provider counts and cash-flow linkage; only limited hedging around future facility ramp.
commit “we're embedding automation and AI to improve workflow and enhance the patient experience.”
commit “Ambient Scribe technology is now used by more than 1,900 providers.”
commit “This transformation enables us to deliver working capital savings and meaningfully contributed to the strong operating cash flow in fiscal 2026.”
VERBATIM AI QUOTES
“As we scale the platform, we're embedding automation and AI to improve workflow and enhance the patient experience.”
— Brian Tyler, Q4 FY2026
“Within the U.S. Oncology Network, Ambient Scribe technology is now used by more than 1,900 providers.”
— Brian Tyler, Q4 FY2026
“These capabilities illustrate how we're using data technology and scale to meaningfully improve our physicians' productivity and dedicate more time to care delivery.”
— Brian Tyler, Q4 FY2026
“We achieved this through strong execution, disciplined planning and continued productivity investments, including the application of technology and automation.”
— Brian Tyler, Q4 FY2026
“As a result, each full-time employee supported 120 more patients this season compared to last year.”
— Brian Tyler, Q4 FY2026
“Recently, we launched an industry-first integrated specialty access and affordability solution designed to address the fragmentation that often delays starting a treatment.”
— Brian Tyler, Q4 FY2026
“As part of our supply chain of the future initiative, this state-of-the-art facility expands critical capacity and features industry-leading automation, including an advanced storage and retrieval system powered by AI and robots, which raised the standard for precision and performance.”
— Brian Tyler, Q4 FY2026
“Across our supply chains, AI-driven inventory planning capabilities are helping us move from reactive to more technology-enabled real-time decision-making.”
— Brian Tyler, Q4 FY2026
“We implemented an advanced planning system that uses AI to connect and orchestrate end-to-end planning across demand, supply, inventory and operations inside an integrated environment.”
— Brian Tyler, Q4 FY2026
“We achieved this operating efficiency while simultaneously making targeted investments to modernize our operations through automation and AI-driven capabilities, which we anticipate will accelerate growth, creating enterprise-wide efficiencies.”
— Britt Vitalone, Q4 FY2026
“Our evolving suite of solutions will accelerate the patient authorization workflow, speed up the process for patients to access medication, introduce transparency with real-time prescription benefit check, and improve affordability with automated searches for financial assistance programs.”
— Brian Tyler, Q3 FY2026
“By applying technology automation and enhancing training to streamline our operations and elevate the customer experience, we are improving our efficiency.”
— Brian Tyler, Q3 FY2026
“Within our North American pharmaceutical business, our teams continue to leverage AI and automation to drive efficiencies.”
— Brian Tyler, Q3 FY2026
“It includes capabilities like agent assist and enhanced live chat.”
— Brian Tyler, Q3 FY2026
“Our early pilots are demonstrating strong results, close to 100% service accuracy and reliability while reducing turnaround time.”
— Brian Tyler, Q3 FY2026
“In the US, we launched an AI chat tool in November to specifically handle customer inquiries related to the Drug Supply Chain Security Act.”
— Brian Tyler, Q3 FY2026
“By enabling natural language answers to complex DSCSA data questions, we prevented 75% of inquiries from being escalated and materially improved first contact resolution.”
— Brian Tyler, Q3 FY2026
“At the same time, we're making targeted investments to modernize our operations through automation and AI-driven capabilities, which we anticipate will accelerate growth while creating enterprise-wide efficiencies.”
— Britt Vitalone, Q3 FY2026
“We were very pleased to say the investments we've been making in technology and that we've call it AI or large language models or generative AI or just other general tech tools.”
— Brian Tyler, Q3 FY2026
“built it digitally native from the start so that we're able to to autonomously resolve 75% of customer inquiries, which is obviously a great outcome for the customer, and it's a great outcome for us for an efficiency and a productivity standpoint.”
— Brian Tyler, Q3 FY2026
ANALYST QUESTIONS ON AI
Q (Q4 FY2026, Michael Cherny): As you think about the ongoing wrap services that you have relative to the oncology as a whole, how is the pipeline changing in terms of additional services you can build out as you get bigger and scaled? And where are the opportunities to continue to expand, whether it's within oncology or other areas, the totality of services to potentially drive incremental revenue and profit streams?
A: including the investments we're making in the practices themselves in things like Ambient Scribe, making the physician work experience, just focus more on patient care, less on administrative burden that we think that helps address burnout, that attracts people to our network, that either individuals or other practices. So that's still, I think, a key part of the growth algorithm.
Q (Q3 FY2026, Allen Lutz): You talked about technology and automation, allowing some of your employees to support more patients in the annual verification season. Can you talk about the specific investments you're making there? And then as a follow-up to Britt, how should we think about the longer-term opportunity to improve margins in that segment?
A: To improve, basically, the workflows we experience internally to allow, for example, emails to be automated and read and queued up to agents in a way they're able to work through them, in a much more rapid fashion. And, and that translated into a a big boost in productivity and what you all know, is a very you know, person intensive, blizzard season for us.
Q (Q3 FY2026, Lisa Gill): I know at our conference, Brian and I talked about, for example, ambient scribing, making that more of the physician more effective. We talked about biosimilars. Is there anything you would call out specifically as to what's driving that margin improvement?
A: we are early in our journey of automating and and building AI capabilities for our customers, but we are seeing that have an impact, and we would expect that impact will continue to build over time.
Q (Q3 FY2026, Elizabeth Anderson): Given the IT investments you talked about in response to Alan's questions and certainly makes sense in the long term vision of the company. If we think about your cap deployment priorities and always talked about this portfolio management, should we expect sort of a shift more towards those internal growth investments versus what we've seen recently in terms of being more acquisitive?
A: we have continuously know, for the last many years, been investing back into our businesses to innovate new products, add new features, extend our differentiation, and we've similarly deployed capital sometimes to acquire capability that we think is is is better to acquire than take the time to build internally.